A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (Glo-BNHL)
Sponsor: ADC Therapeutics S.A.
A PHASE2/PHASE3 clinical study on B-cell Non Hodgkin Lymphoma, this trial is actively recruiting participants. The trial is conducted by ADC Therapeutics S.A. and has accumulated 8 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2/PHASE3
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE2/PHASE3
-
Dec 2024 — Jan 2026 [monthly]
Recruiting PHASE2/PHASE3
Status: Active Not Recruiting → Recruiting
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE2/PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2/PHASE3
Status: Not Yet Recruiting → Active Not Recruiting
▶ Show 3 earlier versions
-
Jul 2024 — Aug 2024 [monthly]
Not Yet Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
May 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Sep 2023 — May 2024 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- ADC Therapeutics S.A.
- Cancer Research UK
- Fight Kids Cancer
- Regeneron Pharmaceuticals
- University of Birmingham
For direct contact, visit the study record on ClinicalTrials.gov .